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Fatty acid oxidation (FAO)The heart is an omnivore organ that requires constant energy production to match its functional demands. In
the adult heart, adenosine‐5′‐triphosphate (ATP) production occurs mainly through mitochondrial fatty acid
and glucose oxidation. The heart must constantly adapt its energy production in response to changes in sub-
strate supply and work demands across diverse physiologic and pathophysiologic conditions. The cardiac
myocyte maintains a high level of mitochondrial ATP production through a complex transcriptional regulato-
ry network that is orchestrated by the members of the peroxisome proliferator-activated receptor gamma
coactivator-1 (PGC-1) family. There is increasing evidence that during the development of cardiac hypertro-
phy and in the failing heart, the activity of this network, including PGC-1, is altered. This review summarizes
our current understanding of the perturbations in the gene regulatory pathways that occur during the devel-
opment of heart failure. An appreciation of the role this regulatory circuitry serves in the regulation of cardiac
energy metabolism may unveil novel therapeutic targets aimed at the metabolic disturbances that presage
heart failure. This article is part of a Special Issue entitled:Cardiomyocyte Biology: Cardiac Pathways of Differ-
entiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
To meet the workload demands of a constant pump, the mamma-
lian heart requires an incredibly high capacity for energy production.
The ability of the heart to store energy, however, is limited. Therefore,
the capacity to produce ATP in the heart must be tightly matched
with work demands and fuel delivery. Much of this regulation occurs
through a complex network of transcription factors that respond to
changes in substrate (fatty acids and glucose) delivery, oxygen avail-
ability, and a myriad of physiological conditions.
The mitochondrion serves as the principal energy-producing or-
ganelle in the heart and accounts for up to 40% of the cardiac myocyte
volume. Under normal conditions, 60–80% of ATP production in the
heart is derived from mitochondrial fatty acid β-oxidation. The re-
mainder is from carbohydrate (glucose and lactate) and to a lesser
degree, ketone body oxidation. However, the heart is extremely met-
abolically ﬂexible, capable of changing fuel source depending on sub-
strate availability or hormonal milieu (e.g. insulin levels). Structural
changes of the heart including physiological and pathological forms
of cardiac hypertrophic growth are also associated with changes in
fuel selection and energy-producing capacity. In the setting of heartocyte Biology: Cardiac Pathways
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l rights reserved.failure, perturbations in cardiac energy metabolism have numerous
consequences including a reduction in capacity and efﬁciency of mi-
tochondrial respiration and ATP production. It is now recognized
that the failing heart is “energy starved”. This review focuses on the
gene regulatory pathways controlling mitochondrial energy produc-
tion in the cardiac myocyte with an emphasis on the dysregulation
that occurs during development of heart failure.
2. Changes in mitochondrial energy transduction and
ATP generation
2.1. Energy production
The concept of the “energy starved” failing heart has been exten-
sively reviewed elsewhere [1] and will not be addressed in detail
here. It is well known that levels of the main storage buffer for ATP,
phosphocreatine (PCr), fall during the development of pathologic car-
diac hypertrophy and during the progression to heart failure. Phos-
phocreatine serves as a shuttle molecule to deliver high-energy
phosphate from ATP produced in the mitochondria to ATP consumed
at the myoﬁbrillar structure. The PCr:ATP ratio has been shown to be
a powerful predictor of mortality in patients with dilated cardiomy-
opathy [2]. A lower total [PCr] in the cell may reﬂect reduced mito-
chondrial respiration and ATP ﬂux. When the [PCr] falls, ADP, AMP
and Pi concentrations rise and activate glycolytic pathways through
increased glucose transport and utilization. Although initially increased
to meet the deﬁciency in energy production, the increased glycolytic
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now recognized that the energetic remodeling in the failing human
heart leads to an approximate 30% decrease in [ATP] [2]. Of particular
interest are the signaling events and mechanisms that lead to de-
creased energy production in the failing heart as well as potential
therapeutic strategies to improve the energy starved heart.
2.2. Energy transduction pathways
There have been a number of studies aimed at assessing the ex-
pression of the components of energy-producing pathways in the
failing heart [3,4]. Similar to the expression of many structural and
contractile proteins, there is a switch to the “fetal gene program” ev-
ident in metabolic enzyme gene expression in cardiac hypertrophy
and failure [5]. Among the most evident changes is a decrease in
the expression of genes encoding fatty acid β-oxidation enzymes
that begins during the development of cardiac hypertrophy. The
rates of FAO have also been shown to be lower in experimental and
human heart failure [6,7]. Coordinate changes in FAO enzyme levels
have now been conﬁrmed by a number of studies using proteomic
approaches to measure changes in mitochondrial protein expres-
sion. For example, a recent mitochondrial comparative proteomic
study in a rat pressure-overload model revealed downregulation of
multiple FAO enzymes [7]. This was associated with increased ex-
pression of glucose oxidation enzymes in the mitochondria. Interest-
ingly, upregulation of cardiac mitochondrial FAO enzyme expression
has been observed in a number of diabetic models consistent with an
activation of fatty acid oxidation rates [8–10]. This likely reﬂects the
high inﬂux of free fatty acids and activating ligands for this pathway
(discussedmore below). Cardiac hypertrophy and failure are also as-
sociated with changes in multiple components of the electron trans-
port chain (ETC). However, even within the same model and study,
divergent responses in different ETC components have been ob-
served, underscoring the complex regulatory network that controls
cardiac mitochondrial energy production [7,11].
Interestingly, exercise training can produce cardiac hypertrophy
that is not characterized by the classic pathologic fetal gene signa-
ture or dysfunction [12]. This so-called “physiologic hypertrophy”
is accompanied by increases in capacity for mitochondrial respira-
tion and ATP synthesis [13]. In addition, some studies have also dem-
onstrated an increase in FAO rates and enzyme expression in
physiological forms of cardiac hypertrophy [14,15]. These observa-
tions raise the possibility that the metabolic effects of exercise train-
ingmay be of some beneﬁt in the setting of heart failure. Indeed, both
animal and clinical studies have demonstrated a beneﬁt from exer-
cise training in both cardiac function and quality of life [16,17].
Finally, advances in clinical imaging have enabled measurements
of myocardial glucose and fatty acid metabolism in humans with
heart failure. The use of positron emission tomography (PET) with
11C-palmitate has demonstrated that a decrease in myocardial FAO
is an independent predictor of left ventricular hypertrophy (LVH)
in hypertension [18]. Furthermore, LVH is associated with a decrease
in both fatty acid metabolism and myocardial efﬁciency [19]. These
studies correlate well with themolecular changes that have been ob-
served in FAO enzyme expression during cardiac hypertrophy.
3. Nuclear receptors: key transcriptional regulators of cardiac fuel
and energy metabolism
A network of transcription factors respond to changes in substrate
availability, as well as growth and stress stimuli, to ensure that the ca-
pacity for fuel burning keeps up with demands. Changes in the levels
and activities of these factors play a key role in the perturbations in
energy production pathways known to occur during the development
of heart failure. In addition, nuclear receptors, as ligand-activated
proteins (discussed further below), have been actively pursued astherapeutic targets for metabolic and cardiovascular disease. The nu-
clear receptor family of transcription factors is now known to regu-
late virtually all aspects of cardiac mitochondrial energy production.
3.1. Peroxisome proliferator-activated receptors (PPARs)
Peroxisome proliferator-activated receptors (PPARs) are members
of the extended nuclear hormone receptor family [20,21]. All 3
isoforms, PPARα, PPARβ/δ and PPARγ, heterodimerize with the reti-
noid X receptor (RXR) and bind a speciﬁc DNA sequence or PPAR re-
sponse element (PPRE) to activate transcription. PPARα is highly
expressed in the myocardium and participates in the regulation of
fatty acid transport and mitochondrial and peroxisomal fatty acid oxi-
dation pathways [22]. PPARα is able to respond to changes in sub-
strate availability through its ligand binding domain. Recent studies
relevant to the liver suggest that long-chain fatty acids and phospho-
lipids can serve as endogenous ligands [23]. In the heart, a recent
study suggests that adipose triglyceride lipase (ATGL) generates bio-
logically active lipid species that serve as PPARα activating ligands
[24]. In support of this, ATGL knockout mice display a profound re-
duction of cardiac FAO gene expression along with multiple mito-
chondrial derangements. This ﬁnding unveils a potential mechanism
in matching cardiac myocyte fatty acid storage and utilization.
The activity of PPARα signaling has been implicated in the known
and divergent substrate shifts in different pathophysiological sce-
narios known to lead to heart failure (Fig. 1). Fatty acid utilization
is known to be downregulated coincident with an increase in glucose
utilization in pressure overload-induced cardiac hypertrophy. In the
insulin resistant and diabetic heart the opposite substrate shifts
occur (Fig. 1). The roles of PPARα in controlling cardiac fuel metabo-
lism in health and disease have been deﬁned, in part, by genetically-
engineered gain-of-function and loss-of function mouse models.
Mice that overexpress PPARα exclusively in the heart (MHC-PPARα)
exhibit increased fatty acid oxidation associated with a decrease in
glucose utilization resulting in an accumulation of triglyceride and
a diabetic-like phenotype [25,26]. These animals exhibit left ventric-
ular hypertrophy and cardiac dysfunction that can be inhibited by
deletion of CD36, a cellular fatty acid import protein [27,28]. High
circulating levels of free fatty acids present in obesity and metabolic
disease may activate cardiac PPARα and contribute to the observed
high FAO rates in this condition (see Fig. 2). In addition, several
groups have also reported an induction of PPARα levels in the dia-
betic mouse heart [29–31]. In contrast, mice lacking PPARα demon-
strate a decrease in fatty acid oxidation and increased glucose
utilization [32–34]. Interestingly, and in contradistinction to the dia-
betic heart, PPARα expression is decreased in human and animal
models of pressure overload-induced cardiac hypertrophy and in
heart failure [5,35–37]. This is in agreement with the observed met-
abolic shift from fatty acid oxidation to glucose metabolism that oc-
curs during the transition to cardiac hypertrophy and heart failure
[38–40].
PPARβ/δ regulates expression of a set of overlapping targets with
PPARα including FAO enzymes. However, in contrast to PPARα,
PPARβ/δ also activates glucose utilization in the heart [41]. Mice
expressing PPARβ/δ in the heart are also relatively resistant to
diet-induced cardiac myocyte lipid accumulation and lipotoxic car-
diomyopathy. Consistent with these observations, cardiac-speciﬁc
deletion of the PPARβ/δ gene in mice results in a decrease in fatty
acid and glucose oxidation rates concomitant with a decrease in
the expression of genes in both pathways [42].
The role of cardiac PPARγ is less well understood. Although it is
expressed at much lower levels in the heart compared to either
PPARα or PPARβ/δ, deleterious effects of cardiac PPARγ-deﬁciency
in mice have been reported by independent groups [43,44]. Cardiac
overexpression of PPARγ also leads to cardiac dysfunction with
lipid accumulation and mitochondrial abnormalities [45]. Therefore,
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necessary for proper cardiac function.
3.2. Estrogen-related receptor (ERR)
Also belonging to the nuclear receptor superfamily, the estrogen-
related receptor (ERR) family is composed of three members, ERRα,
ERRβ and ERRγ [46–48]. Endogenous ligands for ERRs have not been
identiﬁed and crystallography studies suggest that the ligand-
binding pocket of ERRα may be too small for any to exist [49].
ERRα and ERRγ are enriched in tissues with high oxidative metabol-
ic rates such as the heart.
ERRα controls the expression of many genes involved in energy
metabolism pathways including cellular fatty acid transport, mito-
chondrial and peroxisomal fatty acid oxidation and mitochondrial
respiration [50]. ERRα also activates expression of PPARα providing
an additional layer of cross-regulation [50]. Genome-wide associa-
tion studies have determined that ERRα and ERRγ likely act as
nonobligatory heterodimers and target a common set of promoters
[51]. ERRα is required for the adaptive response to hemodynamic
stress as loss-of-function results in decompensated heart failure
when mice are subjected to left ventricular pressure overload. This
is associated with myocardial phosphocreatine depletion andFig. 1. Divergent substrate utilization in the hypertensive, hypertrophic and insulin resistant
lizations in the cardiac myocyte. Cardiac hypertrophy frequently associated with hypertensio
fatty acid oxidation (FAO). PPARα activity is central to the control of FAO and its modulatio
source. However, both substrate switches eventually lead to mitochondrial dysfunction con
PPARα, peroxisome proliferator-activated receptor alpha; PCr, phosphocreatine; TAG, triacreduced maximal ATP synthesis [52]. Furthermore, expression of
ERR target genes including those involved in glucose metabolism,
FAO and the ETC are signiﬁcantly downregulated in human heart
failure samples suggesting that interruption of normal ERR function
contributes to the pathophysiology of heart failure.
A critical role for ERRγ in the control of cardiac energy metabolism
has also been demonstrated in loss-of-function studies. ERRγ knock-
out mice display a downregulation of several ERR targets in the
heart, exhibit cardiomyopathy, and die immediately following birth.
The early postnatal death in these animals probably results from the
inability to transition from glucose to fatty acid utilization following
birth [53].
4. PPARγ coactivator-1 (PGC-1)
The discovery of peroxisome proliferator-activated receptor
(PPAR)γ coactivator-1α (PGC-1α) provided the ﬁrst clue as to how
the complex transcriptional regulatory circuit controlling cardiac
metabolism was orchestrated in accordance with energy demands.
PGC-1α was ﬁrst cloned in brown adipose tissue as a PPARγ
interacting protein [54]. The PGC-1 family also contains two other
members, PGC-1β and PGC-1-related coactivator (PRC) [55,56].
PGC-1α is an inducible transcriptional coregulator activated by, diabetic hearts. The speciﬁc etiology of heart disease promotes different substrate uti-
n and ischemia promotes glucose utilization while obesity and diabetes favor increased
n in hypertrophy (down) or diabetes (up) contributes to the observed changes in fuel
tributing to the progression of clinical heart failure. LVH, left ventricular hypertrophy;
ylglycerol.
PGC-1
DGAT1/
SCD1
CD36
Obesity/Caloric excess
TAG
FA -oxidation
PPAR
Fig. 2.Mechanistic model of myocardial lipid accumulation relevant to obesity-related forms of heart failure that occur in the diabetic heart. There is an inﬂux of fatty acids into the
cardiac myocyte in the setting of obesity and insulin resistance. Excess intracellular fatty acids are stored as triglycerides or can act as activating ligands for PPARα. At least in the
early stages of insulin resistance, activation of PPARα results in increased mitochondrial fatty acid β-oxidation. However, PPARα also activates fatty acid import pathways, including
CD36, to begin a vicious cycle of increased import and storage of fatty acids. Eventually, PGC-1 levels fall and mitochondrial and cardiac dysfunction ensues. DGAT1, diacylglycerol
acyltransferase 1; SCD1, stearoyl-CoA desaturase 1; TAG, triacylglycerol; PPARα, peroxisome proliferator-activated receptor alpha; PGC-1, PPARγ coactivator-1.
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posure and exercise [57–59]. PGC-1α expression in the heart is in-
duced during heart development concomitant with the
mitochondrial burst that occurs just before birth [60]. An increase
in PGC-1α cardiac expression is also observed following acute and
chronic exercise training which may be dependent, in part, upon in-
sulin growth factor 1 (IGF1) signaling [61]. Overexpression studies
conﬁrmed that PGC-1α directly interacts and activates the targets
of PPARα [62], PPARβ/δ [63], ERRα and ERRγ [64–66]. These results
suggest that PGC-1 integrates physiologic signals and developmental
cues to regulate virtually all aspects of mitochondrial function
(Fig. 3).
Somewhat surprisingly, myocardial mitochondrial volume and
ventricular function are not diminished in PGC-1α knockout animals
[67,68]. The relatively mild phenotype is related to functional redun-
dancies between PGC-1α and PGC-1β. Indeed, disruption of both the
PGC-1α and PGC-1β genes prevents perinatal mitochondrial biogen-
esis in the heart causing cardiomyopathy and death shortly after
birth [69]. Given its critical role in mitochondrial function, a logical
question is whether dysregulation of PGC-1 is involved in the patho-
genesis of the “energy-starved” phenotype of the failing heart. The
changes in fuel selection and mitochondrial function in the hyper-
trophied and failing heart are likely consequences of dysregulation
of the PGC-1 circuit. Consistent with this notion, the expression of
PGC-1α is downregulated in both animal models and human heart
failure samples [5,70,71]. In addition, PGC-1α and PGC-1β deﬁcient
mice develop heart failure following pressure overload [72,73].
Taken together, these data suggest that deactivation of PGC-1 and ac-
companying metabolic derangements contribute to the develop-
ment of heart failure. Furthermore, the activity of PGC-1 may be
altered independent of its expression by post-translational modiﬁca-
tions including phosphorylation and acetylation. PGC-1α activitycan be increased through direct phosphorylation by AMPK [74]. Fur-
ther regulation of PGC-1α activity is controlled by opposing actions
of GCN5 (acetylation) [75] and SIRT1 (deacetylation) [76]. Changes
in intracellular energy production and nutrient availability known
to occur during heart failure impact the activity of both AMPK and
SIRT1. However, the role of alterations in the upstream signaling
pathways and the consequence of these changes on PGC-1 activity
during the development of heart failure have not been fully explored
in animal models or humans.
5. Other relevant transcription factors
5.1. MEF2
The myocyte enhancer factor-2 transcription factor has been
shown to regulate many growth and remodeling genes during car-
diac hypertrophy [77]. A link between MEF2A and cardiac metabo-
lism was ﬁrst shown in MEF2A knockout mice which displayed
decreased mitochondrial content and perinatal lethality [78]. Sub-
sequently, MEF2 was shown to directly activate transcription of
PGC-1α [79]. Cardiac MEF2 activity is tightly controlled by class II
histone deacetylases including HDAC4 and HDAC5. Class II HDACs
have been shown to be signal-responsive inhibitors of MEF2 and
pathologic cardiac growth [80,81]. In this context, dysregulation of
MEF2 activity could contribute to perturbations in cardiac energy
production during hypertrophy and failure.
5.2. NRF-1
Nuclear respiratory factor-1 (NRF-1) was originally identiﬁed
through its binding of the cytochrome c promoter [82]. Subsequent
characterization of its binding site demonstrated that NRF-1 regulates
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transport chain complex subunits [83]. Moreover, NRF-1 induces
the expression of the mitochondrial transcription factor A (Tfam),
that plays a role in mitochondrial DNA transcription, stabilization
and maintenance [84,85]. NRF-1 knockouts are embryonically lethal
at day 6.5 and show impaired mitochondrial membrane potential as
well as a decrease in the mitochondrial DNA content [86]. Interest-
ingly, NRF-1 also induces MEF2 expression to coordinate expression
of mitochondrial respiratory chain subunits [87]. Along with direct
regulation of PGC-1α by MEF2A, this network provides a positive
feedback loop through NRF-1, MEF2A, and PGC-1α to control mito-
chondrial function and content in the cardiac myocyte.
6. Implications for the development of new therapeutic approaches
targeting cardiac energy metabolism
The rates of heart failure are rising as the population continues to
age. There is a clear unmet medical need for new therapeutic ap-
proaches for this problem, particularly aimed at the early stages. In-
deed, the prognosis for heart failure patients on current therapies
remains dismal, with a 5-year mortality rate of around 50% [88]. In
addition, a signiﬁcant proportion of heart failure involves preserved
ejection fraction (HFpEF) or so-called diastolic heart failure, for
which there is no evidence-based medical treatment that improves
mortality in these patients [89]. The traditional emphasis on heart
failure with decreased ejection fraction and lack of reliable animal
models has also limited our understanding of themetabolic derange-
ments that occur in HFpEF. There is currently no heart failure thera-
peutic that directly targets metabolism or energy production.
6.1. Myocardial substrate utilization
To date, the most extensively studied and cited potential thera-
peutic intervention, particularly in the setting of ischemia, is to de-
crease mitochondrial FAO and force a shift to increased glucose
utilization. This shift would lead to a more oxygen efﬁcient state in
terms of ATP production. It should be noted, however, that the utility
of this approach, particularly in non-ischemic scenarios remains to
be proven. Several strategies have been employed in preclinical
studies including targeting free fatty acid uptake, fatty acid entry
into the mitochondria or direct FAO inhibition [3]. Although certain
agents have now been approved for the treatment of angina, none
have progressed far for the treatment of chronic heart failure.Fig. 3. PGC-1α control of cardiac mitochondrial function. PGC-1α integrates signals from ph
rect interaction with multiple transcription factors drives expression of proteins involved i
kinase; PGC-1α, PPARγ coactivator-1 alpha; PPARα, peroxisome proliferator-activated recep
ratory factor; ETC, electron transport chain; OXPHOS, oxidative phosphorylation.However, some evidence suggests that partial FAO inhibitors, such
as trimetazidine, have a positive effect on cardiac function and re-
modeling in addition to their anti-anginal activities [90]. Deﬁnitive
clinical trials are needed to establish these initial ﬁndings in chronic
heart failure.
Not all evidence supports the strategy to inhibit FAO. Cardiac
overexpression of pyruvate dehydrogenase kinase 4 (PDK4) in trans-
genic mice leads to very high FAO rates and decreased glucose utili-
zation [91]. Surprisingly, however, these mice have normal recovery
following ischemia/reperfusion injury and some evidence for pro-
tecting against myocyte lipid accumulation due to a high fat diet,
which would potentially be beneﬁcial in diabetic forms of cardiac
dysfunction. PGC-1α levels and target gene expression are also
upregulated in these mice. These results underscore that a “one-size
ﬁts all” approach to modulating fuel utilization may not be optimal
and that therapies targeting myocardial energy production will
need to be tailored to the speciﬁc disease state. Moreover, strategies
to increase fatty acid catabolism in heart must be matched with a
corresponding increase in mitochondrial respiratory capacity. Lastly,
one therapeutic approach may be well-suited for a diabetic patient
with ectopic lipid accumulation and high FAO rates but ineffective
or even detrimental to a patient with hypertension and a different
metabolic proﬁle.
6.2. PGC-1 as a therapeutic target to maintain or increase mitochondrial
function
Given the importance of PGC-1 in the regulation of virtually all
aspects of mitochondria, it is reasonable to hypothesize that strate-
gies to increase PGC-1 levels and/or activity will increase energy pro-
duction in the failing heart. However, this concept has not been
deﬁnitively tested. The approach in pre-clinical models is complicat-
ed by the fact that cardiac overexpression of PGC-1α results in car-
diomyopathy as a result of uncontrolled mitochondrial biogenesis
[60]. To date, effective small molecule activators of PGC-1α have
not been developed. However, cardiac overexpression of PGC-1β is
cardioprotective in a lipopolysaccharide (LPS) challenge model
[92]. Upstreammodulators of PGC-1may also serve as interventional
points. Speciﬁc inhibition or activation of GCN5 and SIRT1, respec-
tively, would be predicted to activate PGC-1. Modulation of each of
these factors has been shown to increase PGC-1 activity [93,94]. De-
ﬁnitive studies are needed to establish the beneﬁt of PGC-1 activa-
tion in the setting of heart failure.ysiologic stimuli as well as upstream modulators such as sirtuins (SIRT) and AMPK. Di-
n all aspects of mitochondrial function. SIRT1, sirtuin 1; AMPK, AMP-activated protein
tor alpha; RXR, retinoid X receptor; ERR, estrogen-related receptor; NRF, nuclear respi-
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Ligands for speciﬁc nuclear receptors, particularly the PPARs,
have been developed and, in some cases, serve to increase the inter-
action with PGC-1. Data with PPARα ligands in experimental heart
failure models has been mixed [95]. Clinically, PPARα ligands have
a very favorable safety proﬁle; however, they have not been speciﬁ-
cally tested in a heart failure population. Moreover, PPARα ligands
would theoretically be restricted to those patients with reduced
myocardial FAO. PPARα activation may actually participate in the
development of lipotoxic cardiomyopathy in the setting of obesity
and diabetes. In addition, the extra-cardiac effects of PPARα activa-
tion must be considered.
As discussed above, ERRs also interact with PGC-1 to drive virtual-
ly all aspects of mitochondrial biogenesis. In contrast to the PPARs,
the relatively small ligand binding domain has hindered the develop-
ment of ERR activating ligands. ERRγ would appear to offer the best
target in this regard.6.4. Lipid storage pathways
Perturbations in lipid handling and storage in the cardiac
myocyte may also impact energy production in the heart, especially
in the cardiac dysfunction associated with obesity and diabetes.
Mice deﬁcient in stearoyl-CoA desaturase (SCD1), the rate-limiting
enzyme in the biosynthesis of monounsaturated fatty acids, has
been shown to decrease cardiac lipid accumulation and improve car-
diac function on the leptin-deﬁcient ob/ob background [96]. Loss of
SCD1 also decreased PPARα levels and β-oxidation rates observed in
ob/ob mice. Clinical development of SCD1 inhibitors, however, has
been problematic due to unwanted side effects. Similar effects
have been observed with the deletion of diacylglycerol acyltrans-
ferase 1 (DGAT1), which catalyzes the ﬁnal step in triglyceride syn-
thesis. Cardiac triglyceride accumulation is reduced and increases in
PPARα, β-oxidation, and fatty acid import genes are inhibited when
DGAT1 knockout mice are placed on a high-fat diet [97]. A remaining
question is the fate of the unstored fatty acids in the absence of
DGAT1 activity. However, at least one study suggests that these are
shuttled to the mitochondrial β-oxidation pathway [98]. Taken to-
gether, these data suggest that inhibition of cardiac lipid accu-
mulation could serve as a promising therapeutic target in the
development of lipotoxic cardiomyopathy.7. Concluding remarks
The healthy heart has an amazing capacity to shift substrate uti-
lization preferences in response to pathophysiologic stimuli to meet
its energy needs. This fuel utilization ﬂexibility becomes constrained
during the development of heart failure. In addition to changes in
structural and contractile proteins, myocardial energy metabolism
is remodeled during cardiac hypertrophy and failure. Importantly,
different forms of cardiac disease, such as hypertension/ischemia
versus obesity/diabetes are characterized by distinct and direc-
tionally different alterations in cardiac fuel metabolism. These
changes are driven, in part, by a complex transcriptional regulatory
network that responds to numerous inputs including nutrient avail-
ability and increased workload. There is a prime opportunity and
medical need to develop therapeutics that directly address the
underlying metabolic derangements that occur early during the de-
velopment of heart failure. This could, in essence, lead to a more
precise or personalized approach to this problem, and at an early
stage. In the long-term, such therapies could, perhaps, be tailored
to the etiology of heart failure and the accompanying metabolic
derangements.Disclosures
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